This product is a second-generation oral sulfonylurea hypoglycemic drug. It is a highly active pancreatic beta cell agent that binds to specific receptors on the pancreatic beta cell membrane and can induce the production of appropriate amounts of insulin to lower blood sugar concentration.

This product is a central antitussive drug that can inhibit the cough center in the medulla oblongata to produce an antitussive effect. Its antitussive effect is equal to or slightly stronger than that of codeine. The general therapeutic dose does not inhibit breathing, and long-term use is non-addictive and non-tolerant. This product is well absorbed orally and takes effect within 10-30 minutes after taking the drug.

Sulfonylurea is an oral hypoglycemic diabetes treatment drug. It lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, it can restore the peak of first-phase insulin secretion in response to glucose and increase first-phase insulin secretion. The insulin secretion response induced or stimulated by glucose after a meal is significantly increased. At the same time, it partially inhibits platelet adhesion and aggregation, reduces platelet activity markers (P-thromboglobulin, thromboxane B2), and produces fibrinolytic activity on the vascular endothelium (increases tPA activity).

Antiviral drug. It has an inhibitory effect on herpes simplex virus, varicella zoster virus, cytomegalovirus, etc. in vitro. After entering the cells infected by herpes virus, it competes with deoxynucleoside for viral thymidine kinase or cell kinase, and the drug is phosphorylated into activated acyclovir triphosphate, which inhibits viral replication by interfering with viral DNA polymerase and binding to the growing DNA chain. It has a special affinity for viruses, but has low toxicity to mammalian host cells.

A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobic bacteria, Chlamydia and Mycoplasma, etc. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.